Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effects of vernakalant and flecainide on atrial contractility in patients with atrial fibrillation De effecten van vernakalant en flecaïnide op de atriale contractiliteit bij patiënten met atriumfibrilleren

Next Previous
X
Search
Trial Profile

Effects of vernakalant and flecainide on atrial contractility in patients with atrial fibrillation De effecten van vernakalant en flecaïnide op de atriale contractiliteit bij patiënten met atriumfibrilleren

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 20 Jan 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Flecainide (Primary) ; Vernakalant (Primary)
  • Indications Atrial fibrillation
  • Focus Therapeutic Use

    • Most Recent Events

    • 19 Jul 2012 Planned initiation date 1 Aug 2012, lead trial investigators added and planned number of patients changed from 50 to 70 as reported by ClinicalTrials.gov record.
    • 19 Jul 2012 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health NCT01646281).
    • 19 Jul 2012 Planned End Date changed from 25 Jun 2013 to 1 Aug 2013 as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top